{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:24:14Z","timestamp":1790691854733,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:sec id=\"ab-cbr240014-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Patients with high-risk newly diagnosed multiple myeloma (NDMM) often have poor outcomes with standard treatments, necessitating novel effective frontline therapies to enhance clinical outcomes. GC012F, a B-cell maturation antigen\/CD19 dual-targeting chimeric antigen receptor (CAR) T-cell therapy, has been developed on the novel FasTCAR platform. Notably, its use as a frontline therapy for patients with high-risk NDMM who are eligible for transplant has not been thoroughly explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240014-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the safety, pharmacokinetics, and patient health and survival outcomes associated with GC012F in individuals with NDMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240014-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>Patients were enrolled in this single-arm, open-label phase 1 cohort study between June 28, 2021, and June 1, 2023 (the data cutoff date). All patients included in this study were treated at a single center, Shanghai Changzheng Hospital. The patients in the efficacy evaluation were followed up for a minimum period of 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240014-7\">\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>\n                      Patients underwent 2 cycles of induction therapy, followed by GC012F infusion (at 1\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      cells\/kg, 2\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      cells\/kg, or 3\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      cells\/kg).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240014-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary goals were to assess the safety, efficacy, and pharmacokinetics of GC012F at various dose levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240014-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 22 patients receiving GC012F treatment, 6 experienced mild to moderate cytokine release syndrome (grade 1-2) and none experienced neurotoxic effects. Nineteen patients were included in the efficacy evaluation, and all 19 patients showed stringent complete responses and achieved minimal residual disease negativity. The treatment\u2019s effectiveness was consistent across different dose levels. GC012F demonstrated a rapid response, with a median time to first stringent complete response of 84 days (range, 26-267 days) and achieving minimal residual disease negativity within 28 days (range, 23-135 days). The CAR T-cell expansion was robust, with a median peak copy number of 60\u202f652 copies\/\u03bcg genomic DNA (range, 8754-331\u202f159 copies\/\u03bcg genomic DNA), and the median time to median peak copy number was 10 days (range, 9-14 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-cbr240014-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this single-arm, open-label phase 1 cohort study suggest that GC012F may be a safe treatment associated with positive health and survival outcomes for patients with high-risk NDMM eligible for transplant. Owing to the small sample size, further studies with larger cohorts and longer follow-up durations are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.2172","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T11:39:34Z","timestamp":1721907574000},"page":"1259","source":"Crossref","is-referenced-by-count":29,"title":["B-Cell Maturation Antigen\/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma"],"prefix":"10.1001","volume":"10","author":[{"given":"Wanting","family":"Qiang","sequence":"first","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"Gracell Biotechnologies Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqi","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gracell Biotechnologies Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianjun","family":"Shen","sequence":"additional","affiliation":[{"name":"Gracell Biotechnologies Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Weng","sequence":"additional","affiliation":[{"name":"Gracell Biotechnologies Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[{"name":"Gracell Biotechnologies Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenling","family":"Li","sequence":"additional","affiliation":[{"name":"Gracell Biotechnologies Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"29","key":"cbr240014r1","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project.","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"26","key":"cbr240014r2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group.","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"cbr240014r3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status.","volume":"97","author":"Du","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"cbr240014r4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up.","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"cbr240014r5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma.","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"cbr240014r6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma.","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"cbr240014r7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12185-013-1293-0","article-title":"Multiple myeloma-initiating cells.","volume":"97","author":"Hosen","year":"2013","journal-title":"Int J Hematol"},{"issue":"10","key":"cbr240014r8","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"cbr240014r9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"cbr240014r10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"cbr240014r11","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma.","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"cbr240014r12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"issue":"16_suppl","key":"cbr240014r13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting FasT CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM).","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"cbr240014r14","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"21","key":"cbr240014r15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2821602\/jamaoncology_qiang_2024_br_240014_1726602735.9083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:34:30Z","timestamp":1726749270000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2821602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.2172","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}